510(k) Report

510(k) · Cleared

Cleared

Elecsys Cea on the Elecsys 1010

K980887510(k) TraditionalCleared Jun 29, 1998112-day reviewClass II21 CFR 866.6010

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Boehringer Mannheim Corp. · DHX System, Test, Carcinoembryonic Antigen

Cleared on Jun 29, 1998 as substantially equivalent to K964368 (Boehringer Mannheim Corp., 1997) after a 112-day review. Its family tree reaches back 1 generation to 1997.

Decided
Jun 29, 1998
Review
112 days
Class
Class II
Product code
DHX
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K964368 (1997). 2 ancestors in all. No later device cites it as a predicate yet.

K964368 · Elecsys Cea Assay · Boehringer Mannheim Corp. · 1997199619982000
  1. Root · 1 generation backK964368 Elecsys Cea AssayBoehringer Mannheim Corp. · 1997
  2. This deviceK980887 Elecsys Cea on the Elecsys 1010Boehringer Mannheim Corp. · 1998
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K964368Elecsys Cea AssayBoehringer Mannheim Corp.1997—
0 (this device)K980887Elecsys Cea on the Elecsys 1010Boehringer Mannheim Corp.1998—
FIG. 1 — Lineage of K980887, 1997–1998Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in DHX? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new DHX device

  1. #1 K223921 Access CEAscore 6.6 · 3 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K964368Elecsys Cea Assay
Summary page 3
…page 26 6. Comparison to predicate device The Boehringer Mannheim Elecsys® CEA Assay has been approved for use on the Elecsys 2010 immunoassay analyzer (K964368). The application of the Elecsys® CEA Assay on the Elecsys 1010 immunoassay analyzer is substantially equivalent to the same assa…
Boehringer Mannheim Corp.1997—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.

How does its category compare?

All DHX devices

DHX System, Test, Carcinoembryonic Antigen: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · DHX

2in 2023

2008: 22009: 12020: 12023: 2
2007high 2 (2008) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · DHX

Too few DHX 510(k)s in any year since 2007 to give a median.

Recalls per year · DHX

1in 2015

2010: 12015: 1
2007high 1 (2010) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · DHX

19in 2025

2007: 22008: 112009: 202010: 82011: 142012: 142013: 262014: 152015: 332016: 222017: 72018: 202019: 122020: 142021: 112022: 122023: 152024: 152025: 19
2007high 33 (2015) · low 2 (2007)2025

MAUDE reports naming product code DHX, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—02
20082—011
20091—020
20100—18
20110—014
20120—014
20130—026
20140—015
20150—133
20160—022
20170—07
20180—020
20190—012
20201—014
20210—011
20220—012
20232—015
20240—015
20250—019
20260—0—

What is it indicated for?

Immunoassay for the in vitro quantitative determination of carcinoembryonic antigen in human serum and plasma. The Elecsys CEA assay is further indicated for serial measurement of CEA to aid in the management of cancer patients.

The electrochemiluminescence immunoassay «ECLIA” is intended for use on the Boehringer Mannheim Elecsys 1010 and 2010 immunoassay analyzers.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K980887: Elecsys Cea on the Elecsys 1010.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K980887

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026